Stockreport

Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why [Yahoo! Finance]

Krystal Biotech, Inc.  (KRYS) 
Last krystal biotech, inc. earnings: 11/4 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.krystalbio.com/investors
PDF 4.3%. This was due to the strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress. In May 2023, the FDA approved Vyjuvek, the first ever red [Read more]